Paper23908178
Human epidermal growth factor receptor 2 (HER2)-positive and hormone receptor-positive breast cancer: new insights into molecular interactions and clinical implications.
Montemurro F and 2 others. Ann Oncol, 2013. Cited by 120 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Human epidermal growth factor receptor 2 (HER2)-positive and hormone receptor-positive breast cancer: new insights into molecular interactions and clinical implications. Papers, record 23908178. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/23908178
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Human epidermal growth factor receptor 2 (HER2)-positive and hormone receptor-positive breast cancer: new insights into molecular interactions and clinical implications.
- PubMed
Topics9
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Breast Neoplasms | Major topic |
| Molecular Targeted Therapy | Major topic |
| Erb-b2 Receptor Tyrosine Kinases | Major topic |
| Antineoplastic Combined Chemotherapy Protocols | |
| Drug Resistance, Neoplasm | |
| Female | |
| Humans | |
| Receptors, Estrogen | |
| Receptors, Progesterone |
Source PubMed
Cited by80
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 120 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42170572 | Can neoadjuvant chemotherapy be replaced with immune checkpoint blockade combined with dual anti-HER2 antibodies for HER2-enriched breast cancer? | Transl Breast Cancer Res | 2026 | https://conductscience.org/library/papers/42170572 | PubMed |
| 41899145 | Real-World Outcomes of Neoadjuvant Dual Blockade in HER2-Positive Breast Cancer: The Role of Tumor Biology and pCR. | J Clin Med | 2026 | https://conductscience.org/library/papers/41899145 | PubMed |
| 41584604 | Maintenance therapy in hormone receptor-positive and human epidermal growth factor receptor 2-positive metastatic breast cancer: a real-world multicenter retrospective study. | Front Oncol | 2025 | https://conductscience.org/library/papers/41584604 | PubMed |
| 41547594 | Optimizing adjuvant endocrine therapy in premenopausal patients with HER2-positive, hormone receptor-positive breast cancer. | Breast | 2026 | https://conductscience.org/library/papers/41547594 | PubMed |
| 41446275 | Contrasting low- and high-resolution features for HER2 scoring using deep learning. | J Pathol Inform | 2025 | https://conductscience.org/library/papers/41446275 | PubMed |
| 41402571 | HER2 expression in breast cancer: evidence gaps and challenges. | NPJ Precis Oncol | 2025 | https://conductscience.org/library/papers/41402571 | PubMed |
| 41023545 | Contemporary Nodal Management and Overall Survival of Older Patients with HR-/HER2+ Breast Cancer. | Ann Surg Oncol | 2026 | https://conductscience.org/library/papers/41023545 | PubMed |
| 40720499 | Response Gene to Complement 32 promotes cell proliferation and tamoxifen resistance in breast cancer via elevated FoxM1 expression. | PLoS One | 2025 | https://conductscience.org/library/papers/40720499 | PubMed |
| 40243160 | Characterisation of HER2-Driven Morphometric Signature in Breast Cancer and Prediction of Risk of Recurrence. | Cancer Med | 2025 | https://conductscience.org/library/papers/40243160 | PubMed |
| 40126169 | Molecular shifts in breast cancer following neoadjuvant chemotherapy: a prospective study and review of literature. | Future Oncol | 2025 | https://conductscience.org/library/papers/40126169 | PubMed |
| 40123585 | Innovative Approaches for Molecular Targeted Therapy of Breast Cancer: Interfering with Various Pathway Signaling. | Int J Mol Cell Med | 2025 | https://conductscience.org/library/papers/40123585 | PubMed |
| 39695741 | ERBB2/HOXB13 co-amplification with interstitial loss of BRCA1 defines a unique subset of breast cancers. | Breast Cancer Res | 2024 | https://conductscience.org/library/papers/39695741 | PubMed |
| 39399377 | Targeting LINC00665/miR-199b-5p/SERPINE1 axis to inhibit trastuzumab resistance and tumorigenesis of gastric cancer via PI3K/AKt pathway. | Noncoding RNA Res | 2025 | https://conductscience.org/library/papers/39399377 | PubMed |
| 39355199 | Investigating the Correlation Between Long-Term Response in Patients with Metastatic HER2+ Breast Cancer and the Activity of Regulatory T Cells: A Retrospective Study. | Breast Cancer (Dove Med Press) | 2024 | https://conductscience.org/library/papers/39355199 | PubMed |
| 39009909 | Synthesis, characterization and bioactivity of new pyridine-2(H)-one, nicotinonitrile, and furo[2,3-b]pyridine derivatives. | Mol Divers | 2025 | https://conductscience.org/library/papers/39009909 | PubMed |
| 38667310 | Three-Dimensional Cultivation a Valuable Tool for Modelling Canine Mammary Gland Tumour Behaviour In Vitro. | Cells | 2024 | https://conductscience.org/library/papers/38667310 | PubMed |
| 38231460 | Clinicopathological differences and survival benefit in ER+/PR+/HER2+ vs ER+/PR-/HER2+ breast cancer subtypes. | Breast Cancer | 2024 | https://conductscience.org/library/papers/38231460 | PubMed |
| 37740038 | Differential response of HER2-positive breast cancer to anti-HER2 therapy based on HER2 protein expression level. | Br J Cancer | 2023 | https://conductscience.org/library/papers/37740038 | PubMed |
| 37600670 | HER2-Low Breast Cancer: Current Landscape and Future Prospects. | Breast Cancer (Dove Med Press) | 2023 | https://conductscience.org/library/papers/37600670 | PubMed |
| 37363965 | Safety and Efficacy of Tucatinib, Letrozole, and Palbociclib in Patients with Previously Treated HR+/HER2+ Breast Cancer. | Clin Cancer Res | 2023 | https://conductscience.org/library/papers/37363965 | PubMed |
Genes2
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| ERBB2 | 2064 | PubTator's text mining | https://conductscience.org/library/genes/2064 | NCBI Gene |
| NR4A1 | 3164 | PubTator's text mining | https://conductscience.org/library/genes/3164 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/23908178
GET https://conductscience.org/api/papers/v1/23908178/cited_by?page=2